$FENC

FENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK ® in Japan AT SIOP 2026 ​ ~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occ

Fennec Pharmaceuticals (FENC) will present detailed Phase 2 Pedmark trial results at SIOP 2026. The study evaluated Pedmark's ability to reduce cisplatin-induced hearing loss in Japanese pediatric patients. Pedmark is FDA-approved for this indication. FENC stock is up 2.75% at $10.84.

Sayad Pierre Sargis (Chief Medical Officer) sold 12,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $12.18 ($0.15M total) on 2026-08-31.

Andrade Robert (CHIEF FINANCIAL OFFICER) sold 75,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $11.78 ($0.88M total) on 2026-08-27 under a Rule 10b5-1 trading plan.

Fennec Pharmaceuticals (NASDAQ:FENC) reported Q2 results on an earnings call. Net product sales were $17.1 million, up 78% year over year. Non-GAAP adjusted EBITDA was $2.8 million versus a $1.2 million loss a year earlier. Cash and cash equivalents were $41.2 million at June 30, 2026. Management cited PEDMARK momentum and no quantitative 2026 revenue outlook.

Fennec Pharmaceuticals (NASDAQ:FENC) shares rose about 8% premarket after Q2 results beat estimates. Adjusted EPS was $0.05 vs $0.02 consensus. Revenue was $17.87M vs $16.39M forecast. Net product sales for PEDMARK grew 78% to $17.1M. Adjusted EBITDA turned positive at $2.8M vs a $1.2M loss. Cash was $41.2M.

Insider Monkey highlights nine companies that beat Q2 EPS expectations among 350+ firms reporting by Aug. 11. Reported EPS surprises include RideNow Group (RDNW) $0.16 vs $0.13, Anterix (ATEX) $0.01 vs -$0.17, Super Micro Computer (SMCI) $1.70 vs $0.96, and Fennec Pharmaceuticals (FENC) $0.05 vs $0.01. The rest of the piece shifts to AI themes and promotional content.

Biotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.

FENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001211583 0001211583 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Raykov Rosty sold 9,747 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $9.62 on 2026-06-01 under a Rule 10b5-1 trading plan.